Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) – Equities research analysts at B. Riley issued their FY2017 earnings per share estimates for shares of Sucampo Pharmaceuticals in a research note issued on Tuesday. B. Riley analyst D. Buck forecasts that the biopharmaceutical company will post earnings of $1.14 per share for the year. B. Riley has a “Buy” rating and a $14.00 price objective on the stock. B. Riley also issued estimates for Sucampo Pharmaceuticals’ Q4 2017 earnings at $0.36 EPS, Q1 2018 earnings at $0.26 EPS, Q2 2018 earnings at $0.24 EPS, Q3 2018 earnings at $0.28 EPS, Q4 2018 earnings at $0.37 EPS, FY2018 earnings at $1.15 EPS, FY2019 earnings at $1.55 EPS, FY2020 earnings at $1.90 EPS and FY2021 earnings at $1.75 EPS.
Several other equities research analysts have also recently weighed in on SCMP. Maxim Group set a $23.00 target price on Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 2nd. TheStreet cut Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a research note on Wednesday, August 2nd. Roth Capital set a $30.00 target price on Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 3rd. BidaskClub cut Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 5th. Finally, Leerink Swann initiated coverage on Sucampo Pharmaceuticals in a research note on Monday, August 21st. They set an “outperform” rating and a $15.00 target price for the company. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $16.00.
TRADEMARK VIOLATION NOTICE: “Sucampo Pharmaceuticals, Inc. (SCMP) Forecasted to Post FY2017 Earnings of $1.14 Per Share” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2017/11/18/sucampo-pharmaceuticals-inc-scmp-forecasted-to-post-fy2017-earnings-of-1-14-per-share.html.
Shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) opened at $10.55 on Friday. The company has a debt-to-equity ratio of 7.37, a quick ratio of 4.46 and a current ratio of 5.11. Sucampo Pharmaceuticals has a 12 month low of $9.30 and a 12 month high of $17.55. The firm has a market capitalization of $478.03, a price-to-earnings ratio of 7.09, a price-to-earnings-growth ratio of 3.11 and a beta of 1.38.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.02. The business had revenue of $61.27 million during the quarter, compared to analysts’ expectations of $58.05 million. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.30 earnings per share.
Several large investors have recently made changes to their positions in SCMP. Louisiana State Employees Retirement System increased its holdings in shares of Sucampo Pharmaceuticals by 1.0% during the second quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 100 shares in the last quarter. First Citizens Bank & Trust Co. acquired a new position in shares of Sucampo Pharmaceuticals during the second quarter worth $116,000. JPMorgan Chase & Co. acquired a new position in shares of Sucampo Pharmaceuticals during the second quarter worth $117,000. Pinnacle Associates Ltd. acquired a new position in shares of Sucampo Pharmaceuticals during the second quarter worth $122,000. Finally, Trexquant Investment LP acquired a new position in shares of Sucampo Pharmaceuticals during the third quarter worth $122,000. Institutional investors own 56.79% of the company’s stock.
In related news, insider Jason Patrick Meyenburg purchased 4,000 shares of the stock in a transaction dated Wednesday, September 6th. The stock was bought at an average cost of $12.13 per share, for a total transaction of $48,520.00. Following the completion of the acquisition, the insider now owns 30,228 shares of the company’s stock, valued at $366,665.64. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Sachiko Kuno sold 1,000,000 shares of the company’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $12.00, for a total transaction of $12,000,000.00. The disclosure for this sale can be found here. 4.13% of the stock is currently owned by corporate insiders.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.